Personalized Treatment Recommendations for Relapsed or Refractory Acute Myeloid Leukemia Using Drug Sensitivity Screening and Genetic Testing

What this Trial Is About

Researchers are investigating personalized treatment options for adults with relapsed or refractory acute myeloid leukemia AML, a condition where standard therapies may no longer be effective. This study evaluates whether combining high throughput drug screening HTS with comprehensive molecular testing called HopeSeq can help identify the best treatment choices tailored to each patients unique cancer profile. The research aims to improve decision-making for AML treatment by using detailed genetic and drug sensitivity data. Participants provide extra bone marrow or blood samples during routine procedures. These samples undergo two main tests the Cancer Drug Sensitivity Test CDST high throughput screening, which assesses how the patients cancer cells respond to about 135 drugs or drug combinations, and HopeSeq, a genomic sequencing assay analyzing over 500 genes. Results from these tests are reviewed by a Functional Molecular Tumor Board, which considers the patients clinical history to recommend personalized treatment options. The patients doctor receives these recommendations and, together with the patient, chooses the best treatment plan. Throughout the study, the researchers monitor participants medical records at 6 and 12 months to evaluate how well the test results predicted treatment response, drug sensitivity or resistance, and overall survival. The study does not involve administering any treatments as part of the protocol. Assessments focus on the feasibility of obtaining timely test results, treatment initiation, remission status, and survival outcomes over a one-year period.

Individualized AML Treatment